CARDENE CAP 30MG DIN 00791709
Health Canada record
| Active ingredient(s) | NICARDIPINE HYDROCHLORIDE 30 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C08CA04 NICARDIPINE |
| Original market date | 31-Dec-1990 |
| Current status date | 03-Sep-1998 |
| Source | Health Canada DPD |
Establishment licence of the holder
Syntex S.A. — licence , not currently licensed, last inspection rating I (2025-11-11).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing NICARDIPINE HYDROCHLORIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02162741 | CARDENE 20MG CAPSULES | HOFFMANN-LA ROCHE LIMITED | Capsule | NICARDIPINE HYDROCHLORIDE 20 MG | Cancelled Post Market |
| 02162733 | CARDENE 30MG CAPSULES | HOFFMANN-LA ROCHE LIMITED | Capsule | NICARDIPINE HYDROCHLORIDE 30 MG | Cancelled Post Market |
International API supply for NICARDIPINE HYDROCHLORIDE
1 valid EDQM Certificates of Suitability from 1 holders. 15 active FDA Drug Master Files.
Special Access Programme
This molecule appears on Health Canada's list of drugs most often requested through the Special Access Programme.
Request a quote for CARDENE CAP 30MG